Immix Biopharma (IMMX) said Tuesday six patients dosed in a phase 1b safety run-in segment of a trial of its experimental NXC-201 treatment of relapsed or refractory AL Amyloidosis successfully completed the trial's safety evaluation.
The safety run-in segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells.
Immix said enrollment can now advance across US study sites at a dose of 450 million CAR-T cells.
AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow.
Price: 2.29, Change: -0.01, Percent Change: -0.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。